Cencora ( NYSE:COR ) Full Year 2024 Results Key Financial Results Revenue: US$294.0b (up 12% from FY 2023). Net income... Cencora, Inc.'s ( NYSE:COR ) dividend will be increasing from last year's ...
Drug distributor Cencora plans to buy Retina Consultants of America from Webster Equity Partners in a $4.6 billion deal. RCA is a management services organization that operates a network of retina ...
Cencora's Q4 sales rose 14.7% to $79.1 billion, exceeding $77.65 billion consensus; adjusted EPS increased 16.8% to $3.34. The Retina Consultants of America deal will add nearly 300 retina ...
Cencora (COR) announced that it has entered into a definitive agreement to acquire Retina Consultants of America, a management services organization of retina specialists, from Webster Equity ...
CONSHOHOCKEN, Pa. — CONSHOHOCKEN, Pa. — Cencora, Inc. (COR) on Wednesday reported fiscal fourth-quarter net income of $3.4 million. On a per-share basis, the Conshohocken, Pennsylvania-based ...
Hosted on MSN7mon
Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?For the current fiscal year, Cencora is expected to post earnings of $13.43 per share on $292.23 billion in revenues. This represents a 12.01% change in EPS on a 11.47% change in revenues. For the ...
Nov 6 (Reuters) - Cencora (COR.N), opens new tab will buy Retina Consultants of America from private-equity firm Webster Equity Partners for $4.6 billion, the drug distributor said on Wednesday ...
Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback